A Novel Metric for Alzheimer’s Disease Detection Based on Brain Complexity Analysis via Multiscale Fuzzy Entropy

Author:

Cataldo Andrea1ORCID,Criscuolo Sabatina2ORCID,De Benedetto Egidio2ORCID,Masciullo Antonio1ORCID,Pesola Marisa2ORCID,Schiavoni Raissa1ORCID

Affiliation:

1. Department of Engineering for Innovation, University of Salento, 73100 Lecce, Italy

2. Department of Electrical Engineering and Information Technology (DIETI), University of Naples Federico II, 80125 Naples, Italy

Abstract

Alzheimer’s disease (AD) is a neurodegenerative brain disorder that affects cognitive functioning and memory. Current diagnostic tools, including neuroimaging techniques and cognitive questionnaires, present limitations such as invasiveness, high costs, and subjectivity. In recent years, interest has grown in using electroencephalography (EEG) for AD detection due to its non-invasiveness, low cost, and high temporal resolution. In this regard, this work introduces a novel metric for AD detection by using multiscale fuzzy entropy (MFE) to assess brain complexity, offering clinicians an objective, cost-effective diagnostic tool to aid early intervention and patient care. To this purpose, brain entropy patterns in different frequency bands for 35 healthy subjects (HS) and 35 AD patients were investigated. Then, based on the resulting MFE values, a specific detection algorithm, able to assess brain complexity abnormalities that are typical of AD, was developed and further validated on 24 EEG test recordings. This MFE-based method achieved an accuracy of 83% in differentiating between HS and AD, with a diagnostic odds ratio of 25, and a Matthews correlation coefficient of 0.67, indicating its viability for AD diagnosis. Furthermore, the algorithm showed potential for identifying anomalies in brain complexity when tested on a subject with mild cognitive impairment (MCI), warranting further investigation in future research.

Publisher

MDPI AG

Reference36 articles.

1. WHO (2024, February 13). Dementia, World Health Organization. Available online: https://www.who.int/news-room/fact-sheets/detail/dementia.

2. Alzheimer’s disease;Blennow;Lancet,2006

3. Huang, L.K., Kuan, Y.C., Lin, H.W., and Hu, C.J. (2023). Clinical trials of new drugs for Alzheimer disease: A 2020–2023 update. J. Biomed. Sci., 30.

4. A systematic review and methodological analysis of EEG-based biomarkers of Alzheimer’s disease;Modir;Measurement,2023

5. Lois, C., Sari, H., Sidwell, A.B., and Price, J.C. (2020). Neuroimaging in Schizophrenia, Springer.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3